LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Summary

The ultimate clinical aim of this proposed phase I trial is to evaluate the toxicity and determine the recommended phase II dose of combining the effect of LDFWART following administration of docetaxel for 6 cycles in patients with recurrent platinum-resistant ovarian cancer.

Timeline

Start

2014-05

Primary completion

2019-05

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “Study voluntarily stopped by Principal Investigator due to lack of accrual.”

Drugs

Indications